You are here: Industry Insights > NeuroRx

News List

NeuroRx Announces ZYESAMI Trial Met Primary Endpoint americanpharmaceuticalreview
March 30, 2021
NeuroRx reports 60-day results of the Phase 2b/3 trial of intravenously-administered ZYESAMI™ (aviptadil acetate) for the treatment of respiratory failure in critically-ill patients with COVID-19, which is being developed in collaboration with ...
NeuroRx Announces Completion of Data Analysis in Phase 2b/3 Clinical Trial of ZYESAMI™ for the Treatment of COVID-19 Respiratory Failure prnewswire
March 29, 2021
NeuroRx, Inc. announces completion of top line data analysis of the 60-day results in its phase 2b/3 clinical trial, conducted under FDA Fast Track Designation, of ZYESAMI™ (aviptadil acetate) for the treatment of critically-ill patients with COVID-19 ...
NeuroRx reports Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ (aviptadil) in Reducing Hospital Stay among Patients with Respiratory Failure due to Critical COVID-19 prnewswire
February 10, 2021
NeuroRx, Inc. reported preliminary results from their Phase 2b/3 trial of ZYESAMI™ (aviptadil, previously RLF-100) performed in collaboration with Relief Therapeutics Holdings, AG (SIX:RLF;OTCQB:RLFTF) in patients with respiratory failure due to ...
NeuroRx Initiates Study of Inhaled ZYESAMI for Severe COVID-19 with UCI Health americanpharmaceuticalreview
February 09, 2021
NeuroRx announced initiation of a Phase 2/3 clinical trial investigating the role of inhaled ZYESAMI™ (aviptadil) for the treatment of patients with Severe COVID-19 in partnership with UCI Health of the University of California, Irvine.
NeuroRx, Relief, and Quantum Leap Announce Inclusion of ZYESAMI in I-SPY COVID-19 Trial americanpharmaceuticalreview
January 15, 2021
NeuroRx, Relief Therapeutics, and the Quantum Leap Healthcare Collaborative of San Francisco announce that NeuroRx and QLHC have signed a Clinical Trial Participation Agreement for the inclusion of ZYESAMI™ (RLF-100TM: aviptadil) in the I-SPY COVID-19 ...
NeuroRx and Relief Therapeutics announce enrollment of 150 patients in phase 2b/3 trial of RLF-100™ for Critical COVID-19 with Respiratory Failure prnewswire
November 16, 2020
NeuroRx, Inc. and Relief Therapeutics Holdings AG announced that as of today, 150 patients (out of a targeted enrollment of 165) have been enrolled in the ongoing phase 2b/3 trial of RLF-100™ (aviptadil) for treating respiratory failure in patients with..
NeuroRx, Relief Releases RLF-100 Data for COVID-19 Respiratory Failure americanpharmaceuticalreview
October 19, 2020
Relief Therapeutics and NeuroRx has announced topline results from 45 patients assessed in an open-label prospective study where 21 patients admitted to an intensive care unit (ICU) with critical COVID-19 and respiratory failure were treated with ...
NeuroRx Submits EUA Request for RLF-100 for COVID-19, Respiratory Failure americanpharmaceuticalreview
September 30, 2020
NeuroRx has submitted a request for an Emergency Use Authorization (EUA) with the FDA for the use of RLF-100™ aviptadil in patients who are receiving intensive care and who have exhausted all approved treatments.
FDA Grants Inhaled Use IND for RLF-100 for COVID-19 to Prevent Respiratory Failure americanpharmaceuticalreview
August 12, 2020
NeuroRx and Relief Therapeutics announced NeuroRx has been granted Investigational New Drug (IND) permission to test RLF-100 (aviptadil) for inhaled use in patients with moderate and severe COVID-19 in order to prevent progression to respiratory failure.
RLF-100 shown to deliver rapid recovery from respiratory failure in Covid-19 patients pharmaceutical-business-review
August 07, 2020
NeuroRx and Relief Therapeutics said that RLF-100 (aviptadil) delivered quick recovery from respiratory failure in the most critically ill patients suffering from Covid-19 in a phase 2/3 clinical trial.

Previous page 1 2 Next page